Lipocine Inc. (NASDAQ:LPCN) Short Interest Update

Lipocine Inc. (NASDAQ:LPCN) saw a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 77,700 shares, a growth of 108.9% from the January 15th total of 37,200 shares. Based on an average daily volume of 33,200 shares, the days-to-cover ratio is presently 2.3 days. Currently, 1.5% of the company’s shares are short sold.

Lipocine Trading Up 1.8 %

Lipocine stock traded up $0.07 during midday trading on Thursday, reaching $3.60. The stock had a trading volume of 9,051 shares, compared to its average volume of 34,006. Lipocine has a 12 month low of $3.20 and a 12 month high of $11.79. The company has a market capitalization of $19.23 million, a P/E ratio of -4.73 and a beta of 1.23. The company has a fifty day moving average price of $4.66 and a two-hundred day moving average price of $4.67.

Institutional Trading of Lipocine

A hedge fund recently bought a new stake in Lipocine stock. Dimensional Fund Advisors LP bought a new stake in Lipocine Inc. (NASDAQ:LPCN) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned approximately 0.22% of Lipocine at the end of the most recent reporting period. 9.11% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, StockNews.com began coverage on Lipocine in a research note on Monday. They issued a “hold” rating on the stock.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.